Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

ClinicalTrials.gov ID: NCT02814175

Public ClinicalTrials.gov record NCT02814175. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)

Study identification

NCT ID
NCT02814175
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
AbbVie
Industry
Enrollment
246 participants

Conditions and interventions

Interventions

  • adalimumab (ADA) Biological
  • methotrexate (MTX) Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 4, 2016
Primary completion
Sep 22, 2019
Completion
Mar 18, 2020
Last update posted
Nov 22, 2020

2016 – 2020

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
AZ Arthritis & Rheum Research /ID# 161796 Sun City Arizona 85351
LeJenue Research Associates /ID# 200093 Miami Florida 33126
Deerbrook Medical Associates /ID# 158655 Vernon Hills Illinois 60061
Ochsner Clinic Foundation /ID# 155178 Baton Rouge Louisiana 70836-6455
Clinical Pharmacology Study Gr /ID# 161057 Worcester Massachusetts 01605
Shores Rheumatology, PC /ID# 162697 Saint Clair Shores Michigan 48081
Coastal Carolina Health Care /ID# 152088 New Bern North Carolina 28562
PMG Research of Wilmington LLC /ID# 152089 Wilmington North Carolina 28401
Altoona Ctr Clinical Res /ID# 152087 Duncansville Pennsylvania 16635
Metroplex Clinical Research /ID# 162486 Dallas Texas 75231
Swedish Medical Center /ID# 162051 Seattle Washington 98104
West Virginia Research Inst /ID# 157815 South Charleston West Virginia 25309

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02814175, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02814175 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →